Silicon Analogues of the Nonpeptidic GnRH Antagonist AG-045572: Syntheses, Crystal Structure Analyses, and Pharmacological Characterization
| Autor: | David John Miller, John S. Mills, Diana Kuehn, Matthias W. Büttner, Bin Zhu, L. H. Tam, Philip Avlar BioVentures Mitchell, David Tebbe, Christian Burschka, Helen Rapley, Ian C. Gray, Parameswary A. Muniandy, Reinhold Tacke, Matthew J. Barnes, Jürgen O. Daiss, Alan G. Hendrick, Julie B. H. Warneck, Richard Conroy, Graham A. Showell, John Gary Montana |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Silicon Magnetic Resonance Spectroscopy Tetrahydronaphthalenes Stereochemistry Drug Evaluation Preclinical Context (language use) Pharmacology Crystallography X-Ray Biochemistry Gonadotropin-Releasing Hormone Structure-Activity Relationship Hormone Antagonists Pharmacokinetics In vivo Drug Discovery Animals Humans Potency Structure–activity relationship Rats Wistar General Pharmacology Toxicology and Pharmaceutics Furans Receptor Molecular Structure Chemistry Organic Chemistry Antagonist Luteinizing Hormone Molecular Medicine Luteinizing hormone Orchiectomy Receptors LHRH |
| Zdroj: | ChemMedChem. 6:2070-2080 |
| ISSN: | 1860-7179 |
| Popis: | AG-045572 (CMPD1, 1 a) is a nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist that has been investigated for the treatment of sex hormone-related diseases. In the context of systematic studies on sila-substituted drugs, the silicon analogue disila-AG-045572 (1 b) and its derivative 2 were prepared in multi-step syntheses and characterized by elemental analyses (C, H, N), NMR spectroscopic studies (1H, 13C, 29Si), and single-crystal X-ray diffraction. The pharmacological properties of compounds 1 a, 1 b, and 2 were compared in terms of their in vitro potency at cloned human and rat GnRH receptors. Compounds 1 a and 2 were also examined in regard to their pharmacokinetics and in vivo efficacy in both castrated rat (luteinizing hormone (LH) suppression) and intact rat (testosterone suppression) models. The efficacy and pharmacokinetic profiles of 1 a and its silicon-containing analogue 2 appear similar, indicating that replacement of the 5,6,7,8-tetrahydronaphthalene ring system by the 1,3-disilaindane skeleton led to retention of efficacy. Therefore, the silicon compound 2 represents a novel drug prototype for the design of potent, orally available GnRH antagonists suitable for once-daily dosing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text